central nervous system

1 similar search for central nervous system

central nervous system diseases

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

5 headnotes for central nervous system (see all)

More than 10.000 documents for central nervous system

- Fda Approves Gadavist for Central Nervous System Scans
SILVER SPRING, Md., March 15, 2011 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration approved Gadavist (gadobutrol), a gadolinium-based contrast agent, for use in patients undergoing magnetic resonance imaging (MRI) of the central nervous system. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)
- U.S. Newswire
- March 15, 2011
- 21 CFR 882.5550 - Central nervous system fluid shunt and components.
- Code of Federal Regulations - Title 21: Food and Drugs
- Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting
- Federal Register Nbr. 77 FR 20037, April 03, 2012
- Notices
- Health and Human Services Department

- The Tonton Macoutes: The Central Nervous System of Haiti's Reign of Terror
[...] these torturers, kidnapers and extortionists were feared not only by children, but also by the country's general population, as well as by opposition members and business men not willing to make enforced payoffs to the authorities. [...] Haiti suffered an unparalleled and crippling brain drain that robbed the small country of many of its most educated citizens.
- Washington Report on the Hemisphere
- May 31, 2010
- RegeneRx Receives Australian Patent for the Use of TB4 to Treat Central Nervous System Diseases and Tissue Damage.
ROCKVILLE, Md. -- RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX)("the Company" or "RegeneRx") announced today that the Company has been ...
- Business Wire
- May 16, 2011
- Meetings: Peripheral and Central Nervous System Drugs Advisory Committee
- FR, June 25, 2010
- Notices
- Food and Drug Administration
- Oxidation of Ethanol in the Brain and Its Consequences
Acetaldehyde, a toxic byproduct of alcohol (i.e., ethanol) metabolism, has long been suspected of causing at least some of the central nervous system actions of ethanol. However, the data to support such a hypothesis have been difficult to obtain. One roadblock is the very low blood levels of acetaldehyde following ethanol intake and the finding that even elevated acetaldehyde levels in the blood do not easily gain access to the brain. The recent discovery of the oxidation of ethanol to acetaldehyde in the adult brain may help explain the acute effects of ethanol. Acetaldehyde, a toxic byproduct of alcohol (i.e., ethanol) metabolism, has long been suspected of causing at least some of the central nervous system actions of ethanol. However, the data to support such a hypothesis have bee...
- Alcohol Research and Health
- Vol. 29 Nbr. 4, October 2006
- Meetings: Peripheral and Central Nervous System Drugs Advisory Committee
- FR, March 17, 2010
- Notices
- Food and Drug Administration
- Central Nervous System
GENERATING BUZZ Fingolimod Novartis Indication: Multiple sclerosis (Ph.III) What the clinical trials found: In a two-year phase II study, Novartis rep...
- Medical Marketing and Media
- August 21, 2009
- Meetings: Peripheral and Central Nervous System Drugs Advisory Committee
- FR, April 06, 2010
- Notices
- Food and Drug Administration